Affimed (NASDAQ:AFMD) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Affimed (NASDAQ:AFMDFree Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on AFMD. Wells Fargo & Company dropped their target price on Affimed from $30.00 to $25.00 and set an overweight rating on the stock in a report on Monday, April 1st. Cantor Fitzgerald reissued an overweight rating on shares of Affimed in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $41.67.

View Our Latest Research Report on Affimed

Affimed Stock Up 0.1 %

AFMD opened at $7.10 on Thursday. The business has a 50 day moving average price of $5.46 and a two-hundred day moving average price of $5.42. Affimed has a 1-year low of $2.23 and a 1-year high of $8.95. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.23 and a current ratio of 3.25.

Institutional Investors Weigh In On Affimed

Several hedge funds have recently bought and sold shares of the company. EWA LLC bought a new position in Affimed during the 4th quarter worth $89,000. abrdn plc bought a new position in Affimed during the fourth quarter worth $130,000. Vestal Point Capital LP acquired a new stake in Affimed during the fourth quarter worth approximately $341,000. Finally, BNP Paribas Financial Markets grew its position in shares of Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 163,162 shares during the period. 30.82% of the stock is currently owned by institutional investors and hedge funds.

About Affimed

(Get Free Report)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.

Featured Articles

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with's FREE daily email newsletter.